Wednesday, November 16, 2022 4:08:27 PM
_lowenstein,
The Regents of UCLA likely have received royalties from the Specials Program in the UK once it became at least partially a commercially operated program. Up until transfer to Sawston and being run by Advent the program was being run exclusively by a research hospital so likely no royalties. Dr. Linda Liau began reporting a connection to NWBO after Sawston treated their first commercially (non research hospital) treated patient under the Specials Program. Since Dr. Linda Liau is compensated by UCLA she would be required to report the connection to the royalty payments through the Regents no matter how minuscule those payments might be or how negligible any part of that was used as compensation to her out of the overall budget by which the Regents are guided. No need to thank me, just glad to help get us all on the same page. Go NWBO!!!; ). Best wishes.
The Regents of UCLA likely have received royalties from the Specials Program in the UK once it became at least partially a commercially operated program. Up until transfer to Sawston and being run by Advent the program was being run exclusively by a research hospital so likely no royalties. Dr. Linda Liau began reporting a connection to NWBO after Sawston treated their first commercially (non research hospital) treated patient under the Specials Program. Since Dr. Linda Liau is compensated by UCLA she would be required to report the connection to the royalty payments through the Regents no matter how minuscule those payments might be or how negligible any part of that was used as compensation to her out of the overall budget by which the Regents are guided. No need to thank me, just glad to help get us all on the same page. Go NWBO!!!; ). Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
